MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
324.42
-1.59
-0.49%
After Hours: 324.42 0 0.00% 16:10 12/18 EST
OPEN
326.27
PREV CLOSE
326.01
HIGH
328.24
LOW
321.91
VOLUME
2.67M
TURNOVER
--
52 WEEK HIGH
346.38
52 WEEK LOW
245.31
MARKET CAP
174.69B
P/E (TTM)
25.08
1D
5D
1M
3M
1Y
5Y
1D
Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug
Benzinga · 5h ago
Medicare-negotiated drug prices to halve out-of-pocket costs next year: report
Seeking Alpha · 7h ago
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
Benzinga · 9h ago
Amgen (AMGN) Gets a Buy from Piper Sandler
TipRanks · 12h ago
SCHD: This ETF Stinks
Seeking Alpha · 1d ago
EXCLUSIVE-US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers
Reuters · 1d ago
Merck cholesterol, cancer therapies to receive national priority vouchers - report
Seeking Alpha · 1d ago
UPDATE 3-AbbVie, several other pharma companies near MFN deal with Trump, sources say
Reuters · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.